DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
MK-1775 is an investigational drug.
There have been 26 clinical trials for MK-1775. The most recent clinical trial was a Phase 2 trial, which was initiated on September 4th 2018.
The most common disease conditions in clinical trials are Carcinoma, Adenocarcinoma, and Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), AstraZeneca, and Merck Sharp & Dohme Corp.
There are thirteen US patents protecting this investigational drug and one hundred and thirty-two international patents.
Recent Clinical Trials for MK-1775
|Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers||National Cancer Institute (NCI)||Phase 1|
|Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study||National Cancer Institute (NCI)||Phase 1|
|Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer||National Cancer Institute (NCI)||Phase 2|
Top disease conditions for MK-1775
Top clinical trial sponsors for MK-1775
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|MK-1775||Start Trial||Methods and compositions for treatment of cancer and autoimmune disease||THE JACKSON LABORATORY (Bar Harbor, ME)||Start Trial|
|MK-1775||Start Trial||Systems and methods for treating cancer||Dignity Health (San Francisco, CA) The Translational Genomics Research Institute (Phoenix, AZ)||Start Trial|
|MK-1775||Start Trial||Substituted pyrazolo[3,4-d]pyrimidinone derivatives||Banyu Pharmaceutical Co., Ltd. (Chiyoda-Ku, Tokyo, JP)||Start Trial|
|MK-1775||Start Trial||Dihydropyrazolopyrimidinone derivatives||MSD K.K. (Chiyoda-Ku, JP)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|MK-1775||European Patent Office||2724156||2031-06-27||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|